See more : Al Alamiya for Cooperative Insurance Company (8280.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Orgenesis Inc. (ORGS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orgenesis Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Triumph Financial, Inc. (TFINP) Income Statement Analysis – Financial Results
- Man Sang International Limited (0938.HK) Income Statement Analysis – Financial Results
- Actinium Pharmaceuticals, Inc. (ATNM) Income Statement Analysis – Financial Results
- Citigroup Inc. (C) Income Statement Analysis – Financial Results
- Rhythm Co.,Ltd. (7769.T) Income Statement Analysis – Financial Results
Orgenesis Inc. (ORGS)
About Orgenesis Inc.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 530.00K | 36.03M | 35.50M | 7.65M | 33.26M | 18.66M | 10.09M | 6.40M | 2.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.26M | 20.44M | 28.16M | 30.62M | 18.12M | 10.70M | 6.81M | 7.66M | 3.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.00 |
| Gross Profit | -5.73M | 15.59M | 7.34M | -22.97M | 15.14M | 7.96M | 3.28M | -1.26M | -906.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -500.00 |
| Gross Profit Ratio | -1,080.19% | 43.26% | 20.68% | -300.13% | 45.53% | 42.65% | 32.53% | -19.70% | -30.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.09M | 6.01M | 36.64M | 83.99M | 12.46M | 6.46M | 2.48M | 2.16M | 1.07M | 1.69M | 1.64M | 2.31M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 34.62M | 16.16M | 15.40M | 19.35M | 25.25M | 16.61M | 10.69M | 6.45M | 4.04M | 2.88M | 3.82M | 2.68M | 72.35K | 21.17K | 25.65K | 0.00 |
| Selling & Marketing | 464.00K | -566.00K | -687.00K | -380.00K | 1.15M | 1.21M | 599.00K | 397.00K | 326.00K | 144.00K | 187.83K | 140.94K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.62M | 16.16M | 14.71M | 18.97M | 25.25M | 16.61M | 10.69M | 6.45M | 4.04M | 2.88M | 3.82M | 2.68M | 72.35K | 21.17K | 25.65K | 3.00K |
| Other Expenses | 0.00 | 788.00K | -1.33M | 474.00K | 2.04M | -1.02M | 1.63M | 2.12M | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K |
| Operating Expenses | 45.76M | 22.95M | 50.02M | 103.43M | 39.74M | 22.06M | 14.80M | 10.23M | 6.31M | 4.58M | 5.46M | 4.99M | 72.35K | 21.17K | 25.65K | 3.00K |
| Cost & Expenses | 52.01M | 43.39M | 50.02M | 103.43M | 57.86M | 32.75M | 21.60M | 17.88M | 10.19M | 4.58M | 5.46M | 4.99M | 72.35K | 21.17K | 25.65K | 3.50K |
| Interest Income | 0.00 | 1.82M | 943.00K | 1.25M | 498.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.17M | 1.82M | 1.29M | 1.06M | 461.00K | 2.75M | 1.23M | 689.00K | 696.00K | 691.09K | 172.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.56M | 1.98M | 1.86M | 1.44M | 3.81M | 2.62M | 2.60M | 2.92M | 1.99M | 4.55K | 3.26K | 1.41K | 0.00 | 15.00K | 0.00 | 0.00 |
| EBITDA | -60.72M | -8.30M | -15.72M | -94.21M | -18.91M | -12.39M | -9.85M | -9.04M | -2.64M | -4.80M | -5.36M | -5.00M | -72.35K | -6.17K | -25.65K | -3.50K |
| EBITDA Ratio | -11,456.23% | -19.15% | -39.00% | -1,244.08% | -62.73% | -65.47% | -100.96% | -135.77% | -175.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -53.64M | -7.37M | -42.68M | -95.78M | -24.60M | -14.65M | -11.23M | 11.28M | -7.21M | -4.58M | -5.46M | -4.99M | -72.35K | -21.17K | -25.65K | -3.50K |
| Operating Income Ratio | -10,120.00% | -20.45% | -120.22% | -1,251.71% | -73.98% | -78.53% | -111.31% | 176.29% | -242.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.81M | -1.85M | -1.15M | -1.63M | -47.00K | -2.83M | -3.66M | -1.26M | 1.85M | -927.10K | -78.66K | -519.21K | 0.00 | -15.00K | 0.00 | 0.00 |
| Income Before Tax | -64.44M | -11.96M | -17.95M | -96.74M | -25.48M | -17.77M | -13.68M | -10.74M | -5.36M | -5.50M | -5.54M | -5.00M | -72.35K | -36.17K | -25.65K | -3.50K |
| Income Before Tax Ratio | -12,159.43% | -33.20% | -50.56% | -1,264.19% | -76.61% | -95.24% | -135.56% | -167.91% | -180.26% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 473.00K | 209.00K | 108.00K | -1.61M | 563.00K | 1.34M | -1.31M | -1.55M | -900.00K | 691.09K | 172.51K | 9.58K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -55.36M | -12.17M | -18.06M | -95.13M | -26.04M | -18.29M | -12.37M | -9.19M | -4.46M | -5.50M | -5.54M | -5.00M | -72.35K | -36.17K | -25.65K | -3.50K |
| Net Income Ratio | -10,445.47% | -33.78% | -50.87% | -1,243.17% | -78.30% | -98.05% | -122.58% | -143.72% | -150.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.91 | -0.48 | -0.74 | -4.46 | -1.64 | -1.37 | -1.28 | -1.08 | -0.96 | -1.22 | -1.32 | -1.11 | -0.01 | -0.01 | 0.00 | 0.00 |
| EPS Diluted | -1.91 | -0.48 | -0.74 | -4.46 | -1.64 | -1.37 | -1.27 | -1.08 | -0.94 | -1.21 | -1.32 | -1.11 | -0.01 | -0.01 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 29.01M | 25.10M | 24.27M | 21.32M | 15.91M | 13.37M | 9.68M | 8.52M | 4.65M | 4.51M | 4.20M | 4.52M | 6.71M | 6.71M | 6.71M | 6.71M |
| Weighted Avg Shares Out (Dil) | 29.01M | 25.10M | 24.27M | 21.32M | 15.91M | 13.37M | 9.71M | 8.52M | 4.74M | 4.56M | 4.21M | 4.52M | 6.71M | 6.71M | 6.71M | 6.71M |
New Dimensions Trading Discloses Large Position in ORGS / Orgenesis
Fintel reports that New Dimensions Trading has filed a 13G form with the SEC disclosing ownership of 1,370,000 shares of Orgenesis Inc (ORGS).
Orgenesis (ORGS) Q3 2022 Earnings Call Transcript
Orgenesis (NASDAQ:ORGS ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants David Waldman - Investor Relations Vered Caplan - Chief Executive Officer Neil Reithinger - Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark...
Orgenesis Schedules Third Quarter 2022 Business Update Conference Call
GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference...
Orgenesis, Inc's (ORGS) CEO Vered Caplan on Q2 2022 Results - Earnings Call Transcript
Orgenesis, Inc. (NASDAQ:ORGS ) Q2 2022 Earnings Conference Call August 16, 2022 11:00 AM ET Company Participants David Waldman – Investor Relations Vered Caplan – Chief Executive Officer Neil Reithinger – Chief Financial Officer Conference Call Participants Bruce Jackson –...
Orgenesis sees 2Q revenue of $7.2M; eyes future sales from POCare platform
Orgenesis (NASDAQ:ORGS) Inc announced second-quarter 2022 revenue of $7.2 million and provided a business update for the period ending June 30, 2022. The global biotech company also said it secured a $10 million loan from investment firm Metalmark Capital Partners for...
Orgenesis Schedules Second Quarter 2022 Business Update Conference Call
GERMANTOWN, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference...
Orgenesis enters second phase of POCare Platform rollout; sees recurring revenues from long-term contracts for the next 2-3 years
Orgenesis (NASDAQ:ORGS) Inc, the global biotech company working to unlock the full potential of cell and gene therapies, has said it is entering the second phase of its POCare Platform rollout, and expects to benefit from recurring revenue streams from...
Orgenesis says consortium led by its MIDA Biotech subsidiary wins 4 million euro grant supporting cutting edge technology
Orgenesis (NASDAQ:ORGS) Inc said that a consortium led by its subsidiary, MIDA Biotech, has won a 4-million-euro grant under the European Innovation Council Pathfinder Challenge Program which supports cutting-edge science and technology in order to create new market opportunities. The consortium...
Orgenesis inks agreement with certain investors for a private placement for which it expects to receive gross proceeds of approximately $14.8M
Orgenesis (NASDAQ:ORGS) Inc said it has entered into a definitive securities purchase agreement with certain investors for a private placement for which it expects to receive gross proceeds of approximately $14.8 million before deducting related offering expenses. The company said the...
Orgenesis' (ORGS) CEO Vered Caplan on Q4 2021 Results - Earnings Call Transcript
Orgenesis' (ORGS) CEO Vered Caplan on Q4 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports